Latin America Intranasal Drug And Vaccine Delivery Market Size & Outlook
Related Markets
Latin America intranasal drug and vaccine delivery market highlights
- The Latin America intranasal drug and vaccine delivery market generated a revenue of USD 4,074.8 million in 2023.
- The market is expected to grow at a CAGR of 5% from 2024 to 2030.
- In terms of segment, liquid delivery device was the largest revenue generating product in 2023.
- Liquid Delivery Device is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Brazil is expected to register the highest CAGR from 2024 to 2030.
Latin America data book summary
| Market revenue in 2023 | USD 4,074.8 million |
| Market revenue in 2030 | USD 5,732.9 million |
| Growth rate | 5% (CAGR from 2023 to 2030) |
| Largest segment | Liquid delivery device |
| Fastest growing segment | Liquid Delivery Device |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
| Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
Other key industry trends
- In terms of revenue, Latin America region accounted for 6.2% of the global intranasal drug and vaccine delivery market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 22,052.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intranasal Drug And Vaccine Delivery Market Scope
Intranasal Drug And Vaccine Delivery Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Intersect ENT | View profile | 251-500 | Menlo Park, California, United States, North America | http://www.intersectent.com |
| Bespak | View profile | 501-1000 | Lynn, Norfolk, United Kingdom, Europe | http://www.bespak.com |
| OptiNose Inc | View profile | 132 | 1020 Stony Hill Road, Suite 300, Yardley, PA, United States, 19067 | https://www.optinose.com |
| Teleflex Inc | View profile | 14500 | 550 East Swedesford Road, Suite 400, Wayne, PA, United States, 19087 | https://www.teleflex.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| AptarGroup Inc | View profile | 13800 | 265 Exchange Drive, Suite 301, Crystal Lake, IL, United States, 60014 | https://www.aptar.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| 3M Co | View profile | 85000 | 3M Center, St. Paul, MN, United States, 55144 | https://www.3m.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Latin America intranasal drug and vaccine delivery market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 44.02% in 2023. Horizon Databook has segmented the Latin America intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
The healthcare spending of this region is reported to be around 7.6% of GDP, which is third in terms of healthcare spending after North America and Western Europe. Growing health awareness and increasing demand for technologically upgraded medical devices for long-term care are among some key factors expected to boost market growth.
These countries have vibrant research relations with China and Europe. Furthermore, pharmaceutical industries in countries such as Mexico and Brazil have been expanding with untapped market opportunities and investments by foreign countries to expand their regional presence. Increase in chronic diseases in the region has also contributed to a rise in the production of drugs and biologics.
Thus, these factors have been contributing to market growth in Latin American region. Initiatives such as eHealth initiative undertaken by the Pan American Health Organization and WHO in Latin America to improve healthcare infrastructure is likely to further support market growth.
Reasons to subscribe to Latin America intranasal drug and vaccine delivery market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Latin America intranasal drug and vaccine delivery market databook
-
Our clientele includes a mix of intranasal drug and vaccine delivery market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America intranasal drug and vaccine delivery market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Latin America intranasal drug and vaccine delivery market size, by country, 2018-2030 (US$M)
Latin America Intranasal Drug And Vaccine Delivery Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
